177 related articles for article (PubMed ID: 24366299)
1. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.
Bharwani N; Miquel ME; Powles T; Dilks P; Shawyer A; Sahdev A; Wilson PD; Chowdhury S; Berney DM; Rockall AG
Br J Cancer; 2014 Feb; 110(3):616-24. PubMed ID: 24366299
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V
BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
[TBL] [Abstract][Full Text] [Related]
5. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Welsh SJ; Thompson N; Warren A; Priest AN; Barrett T; Ursprung S; Gallagher FA; Zaccagna F; Stewart GD; Fife KM; Matakidou A; Machin AJ; Qian W; Ingleson V; Mullin J; Riddick ACP; Armitage JN; Connolly S; Eisen TGQ
BJU Int; 2022 Aug; 130(2):244-253. PubMed ID: 34549873
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
Ursprung S; Priest AN; Zaccagna F; Qian W; Machin A; Stewart GD; Warren AY; Eisen T; Welsh SJ; Gallagher FA; Barrett T
PLoS One; 2021; 16(10):e0258988. PubMed ID: 34699525
[TBL] [Abstract][Full Text] [Related]
7. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Differentiation of Minimal Fat Angiomyolipoma from Clear Cell Renal Cell Carcinoma.
Li H; Li A; Zhu H; Hu Y; Li J; Xia L; Hu D; Kamel IR; Li Z
Acad Radiol; 2019 May; 26(5):632-639. PubMed ID: 30087067
[TBL] [Abstract][Full Text] [Related]
8. Subtype Differentiation of Small (≤ 4 cm) Solid Renal Mass Using Volumetric Histogram Analysis of DWI at 3-T MRI.
Li A; Xing W; Li H; Hu Y; Hu D; Li Z; Kamel IR
AJR Am J Roentgenol; 2018 Sep; 211(3):614-623. PubMed ID: 29812980
[TBL] [Abstract][Full Text] [Related]
9. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kusuda Y; Harada K; Sakai I; Fujisawa M
Int J Clin Oncol; 2013 Feb; 18(1):81-6. PubMed ID: 22095244
[TBL] [Abstract][Full Text] [Related]
10. Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy.
Kozumi M; Ota H; Yamamoto T; Umezawa R; Matsushita H; Ishikawa Y; Takahashi N; Matsuura T; Takase K; Jingu K
Eur Radiol; 2018 Oct; 28(10):4296-4305. PubMed ID: 29725833
[TBL] [Abstract][Full Text] [Related]
11. Multiple mathematical models of diffusion-weighted magnetic resonance imaging combined with prognostic factors for assessing the response to neoadjuvant chemotherapy and radiation therapy in locally advanced rectal cancer.
Liang CY; Chen MD; Zhao XX; Yan CG; Mei YJ; Xu YK
Eur J Radiol; 2019 Jan; 110():249-255. PubMed ID: 30599868
[TBL] [Abstract][Full Text] [Related]
12. Kidney tumor diffusion-weighted magnetic resonance imaging derived ADC histogram parameters combined with patient characteristics and tumor volume to discriminate oncocytoma from renal cell carcinoma.
van Oostenbrugge TJ; Spenkelink IM; Bokacheva L; Rusinek H; van Amerongen MJ; Langenhuijsen JF; Mulders PFA; Fütterer JJ
Eur J Radiol; 2021 Dec; 145():110013. PubMed ID: 34768055
[TBL] [Abstract][Full Text] [Related]
13. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype.
Goyal A; Sharma R; Bhalla AS; Gamanagatti S; Seth A; Iyer VK; Das P
Acta Radiol; 2012 Apr; 53(3):349-58. PubMed ID: 22496427
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
16. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
18. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and
Uutela A; Ovissi A; Hakkarainen A; Ristimäki A; Lundbom N; Kallio R; Soveri LM; Salminen T; Ålgars A; Halonen P; Ristamäki R; Nordin A; Blanco Sequeiros R; Rinta-Kiikka I; Lantto E; Virtanen J; Pääkkö E; Liukkonen E; Saunavaara J; Ryymin P; Lammentausta E; Osterlund P; Isoniemi H;
ESMO Open; 2021 Aug; 6(4):100208. PubMed ID: 34325107
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade.
Mytsyk Y; Dutka I; Borys Y; Komnatska I; Shatynska-Mytsyk I; Farooqi AA; Gazdikova K; Caprnda M; Rodrigo L; Kruzliak P
Int Urol Nephrol; 2017 Feb; 49(2):215-224. PubMed ID: 27853915
[TBL] [Abstract][Full Text] [Related]
20. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
